Mentari Therapeutics: Stifel initiates coverage with buy rating, $30 target price
MTRI•Stifel initiated coverage of Mentari Therapeutics with a buy rating and a $30 target price.
Related News
Opus Genetics Q3 revenue falls and misses analyst estimates
IRD•
Beam Therapeutics' risto-cel meets primary endpoints in sickle cell trial
BEAM•
Essex Property Trust target price raised to $288 from $286
ESS•
Deutsche Bank raises Fortune Brands Innovations target price to $48 from $41
FBIN•
Founder Group swings to net profit of RM 791,785 for six months ended June 30, 2026
FGL•